Digest
Digest, licence 80015105: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- 2158894 Ontario Inc.
- NPN or DIN-HM
- 80015105
- Status
- Active licence
- Licence date
- 7 December 2009
- Revision date
- 24 September 2019
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Taraxacum officinale Source : Extrait de racine Extraction ratio : 4:1 Dry plant equivalent : 500 mg | 125.0 mg | Not calculated |
| Cynara scolymus Source : Aqueous dried leaf extract Potency : 3.0 % Chlorogenic acid | Not specified | Not calculated |
Non-medicinal ingredients
Stéarate de magnésium, Saccharose, Hydroxypropylcellulose, Modified food starch, Hydrogénophosphate de calcium, Talc, Charcoal, Activated USP
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1.0 Capsule | 3.0 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Improves abdominal symptoms and pain in irritable bowel syndrome. Indicated for dyspeptic complaints including flatulence, early satiety, feeling of fullness, vomiting, nausea, stomach pains, loss of appetite, constipation, fat intolerance, and irritable bowel syndrome. Used for symptomatic treatment of digestive disorders such as flatulence. Increases bile secretion.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80015105
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2019. Photograph the packaging to check whether it has changed.
Has the product changed? Photograph the packaging.